Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/109849| Title: | Update Breast Cancer 2023 Part 1 : early stage breast cancer |
| Author(s): | Hartkopf, Andreas Thomssen, Christoph [und viele weitere] |
| Issue Date: | 2023 |
| Type: | Article |
| Language: | English |
| Abstract: | With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. |
| URI: | https://opendata.uni-halle.de//handle/1981185920/111804 http://dx.doi.org/10.25673/109849 |
| Open Access: |  Open access publication |
| License: |  (CC BY-NC-ND 4.0) Creative Commons Attribution NonCommercial NoDerivatives 4.0 |
| Journal Title: | Geburtshilfe und Frauenheilkunde |
| Publisher: | Thieme |
| Publisher Place: | Stuttgart |
| Volume: | 83 |
| Issue: | 06 |
| Original Publication: | 10.1055/a-2074-0551 |
| Page Start: | 653 |
| Page End: | 663 |
| Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| a-2074-0551.pdf | 864.02 kB | Adobe PDF |  View/Open |